CBX7 over-expression is associated with poor prognosis in ovarian adenocarcinomas through the inhibition of the TRAIL-induced apoptotic pathway [5] and its expression leads to the expansion of cellular lifespan in human prostate primary epithelial cells [6] and in mouse embryonic fibroblasts (MEFs) through the repression of the Ink4a/Arf locus [7]. Here, CDKN2A is linked to ovarian adenocarcinoma.